Neoadjuvant immunotherapy: Revolutionising melanoma treatment | 36 min
Our latest podcast explores the innovative approach of neoadjuvant immunotherapy – administering checkpoint inhibitor immunotherapy before the surgical removal of melanoma. This promising approach...
The role of PRAME immunohistochemistry in the diagnostic approach to melanocytic lesions | 30 min
PRAME is a tumour-associated antigen identified by autologous T-cell epitope in a patient with metastatic cutaneous melanoma. In this presentation Pathologist Dr Robert Rawson...
Unravelling lentigo maligna | 48 min
Lentigo maligna – a subtype of in situ melanoma – presents diagnostic and treatment challenges for clinicians. In this podcast, Dr Michael Rtshiladze leads...
The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists | 40 min
The role of the Pathologist is crucial in the emerging field of neoadjuvant therapy in melanoma. Understanding that their role is fundamental to patient...
Diagnosis and management of uveal melanoma | 44 min
Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic...
Refining pathological response assessment in neoadjuvant therapy for melanoma | 40 min
In this presentation, Pathologist Prof Richard Scolyer AO discusses how neoadjuvant therapy is transforming melanoma patient care. He also answers key questions around neoadjuvant-treated...
The future of melanoma and surgical oncology | 52 min
This presentation was recorded at A/Prof Alexander van Akkooi’s inaugural Australian lecture where he discusses his vision and aims for the future of melanoma...
Critical questions for a melanoma pathologist | 36 min
The role of pathologist in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the...
Toxicity management in melanoma | 45 min
Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of...